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Mutations inmethyl-CpG-binding protein 2 (MECP2) underlie most cases of Rett Syndrome, a neurodevelop-
mental disorder with neurological and somatic impairments. In this issue of Immunity, Cronk et al. (2015) find
that macrophages in MeCP2-deficient mice are abnormal in number, as well as in glucocorticoid, hypoxia,
and inflammatory responses.The immune and nervous systems rely
on a well-orchestrated coordination of
many diverse cell types to maintain ho-
meostasis and survival of an organism.
Besides this commonality in complexity
and importance, it is becoming increas-
ingly apparent that each of these seem-
ingly disparate systems has profound
impact on the other, dynamically linked
in function and by shared molecular
pathways. Consistent with this newly
emerging concept, the paper by Cronk
et al. provides exciting new evidence
that a master gene regulator, methyl-
CpG-binding protein 2 (MeCP2), known
to play critical functions in neural circuit
plasticity and overall nervous system
function, plays key roles in regulating
the immune system (Cronk et al., 2015).
These findings are particularly impactful
in the context of Rett Syndrome,
a neurodevelopmental disorder most
commonly caused by mutations in
MECP2 (Amir et al., 1999). Rett patients
develop normally until approximately
6–18 months followed by developmental
stagnation and regression with autism-
like features (Chahrour and Zoghbi,
2007). Following the regression period,
patients present with an array of neuro-
logical symptoms and somatic impair-
ments. While there has been extensive
and very important work to identify
how mutations in MECP2 lead to neuro-
logical deficits, very little is known
regarding manifestation of the somatic
abnormalities (Banerjee et al., 2012;
Chahrour and Zoghbi, 2007). This
study provides an important clue into
how these somatic impairments might
develop: abnormalities in several macro-
phage populations.600 Immunity 42, April 21, 2015 ª2015 ElsevThe current study builds from earlier
work by the same group in which they re-
placed MeCP2-deficient myeloid-derived
cells with wild-type cells using two
strategies: bone-marrow chimerism in
MeCP2-deficient mice or targeted
MeCP2 expression in myeloid cells using
Lysmcre on a MeCP2-null background
(Derecki et al., 2012). Remarkably, in
either case, several Rett Syndrome-like
phenotypes were attenuated (neurolog-
ical scores, breathing abnormalities, loco-
motor abnormalities, and decreased
weight) and the lifespan of the mice was
significantly improved. Many of these
effects were attributed to microglia, the
brain-resident macrophage; however,
the underlying mechanisms remained
elusive. To more specifically manipulate
MeCP2 in macrophages (including micro-
glia), the authors used a newly generated
Cre line, Cx3cr1cre-ER, crossed with
Mecp2Lox-stop/y mice to re-express
MeCP2 in Cx3CR1-expressing macro-
phages. When tamoxifen was adminis-
tered at symptom onset (approximately
9 weeks), the authors found that weight
loss was attenuated and lifespan was
increased. Thus, these data confirm
earlier findings that macrophage popula-
tions, including microglia, are dysregu-
lated inMeCP2-null mice and introduction
of wild-type macrophages into an other-
wise null background can significantly
attenuate a subset of phenotypes.
How does MeCP2 regulate macro-
phages and, in turn, contribute to pheno-
types in MeCP2-null mice? This was
particularly important to address given
that macrophages express relatively low
amounts of MeCP2 compared to other
resident nervous system cells knownier Inc.to be important contributors to the
pathophysiology of Rett Syndrome (i.e.,
neurons, astrocytes, and oligodendroc-
tyes; Zhang et al., 2014). The authors
show that microglia and other macro-
phages do indeed express MeCP2 and
that global loss of MeCP2 results in
reduced numbers of specificmacrophage
populations: microglia, perivascular
meningeal macrophages, CD64+F4/80+
intestinal macrophages, and Ly6Clo circu-
lating monocytes. Interestingly, data
suggest that reductions in microglia oc-
cured only in late-phenotypic mice (also
accompanied by abnormalities in cell
morphology) and were due to cell death,
while reductions in other macrophages
occurred in pre-phenotypic mice possibly
resulting from failure of Ly6Chi monocyte
progenitors to differentiate in vivo (Fig-
ure 1). No effect was observed in non-
perivascular meningeal macrophages or
splenic red pulp macrophages. Taken
together, these data suggest an intrinsic
vulnerability of certain macrophage sub-
populations at different stages of disease
and by different mechanisms.
Could MeCP2 regulate microglia and
peripheral macrophage populations on
a molecular level? To address this ques-
tion, the authors performed RNA-seq
on whole-brain microglia and peritoneal
macrophages isolated from wild-type
and MeCP2-null mice. Some of the
most interesting and important data from
this paper are in this profiling dataset
where the authors find a common theme
in both cell populations, dysregulation of
genes involved in glucocorticoid sig-
naling, hypoxia responses, and inflamma-
tory responses (Figure 1). Furthermore, at
least in the case of glucocorticoid-related
Figure 1. MeCP2-Dependent Regulation of Microglia, Peripheral Macrophages, and
Monocytes
Under healthy, steady-state conditions, peripheral macrophages and monocytes exist throughout the
body (orange and red, top left). Microglia within the immune-privileged CNS contribute to maintenance
of synaptic connections between presynaptic inputs (yellow) of the presynaptic neuron and dendrites
from the postsynaptic neuron (blue, top left). During early, pre-phenotypic stages in MeCP2-deficient
mice, there are reductions in a subset of peripheral macrophages and Ly6Clo blood monocytes, with no
clear changes in microglia (top right). At late-phenotypic stages, microglia also appear to reduce in num-
ber, changemorphology, and assume a hyper-inflammatory state in the CNS (release of inflammatoryme-
diators, etc., bottom left). At end stages of disease in MeCP2-deficient mice, the structure and function of
brain circuitry is disrupted, often associated with reductions in synaptic connections (bottom right). We
speculate that some of these late changes in connectivity might result from dysregulated inflammatory
and phagocytic functions in microglia.
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be due to direct interaction of MeCP2
with the macrophage genome. These
data emphasize that, in addition to canon-
ical nervous system cell types, MeCP2
expression is specific and important for
the function of vulnerable immune cell
populations.
Taken together, the authors show that
macrophage populations are sensitive
to alterations in MeCP2 expression on a
cellular and molecular level. Furthermore,
macrophage responses to loss of
MeCP2 can have profound impact on
the organism with important implications
for somatic impairments observed inRett Syndrome. This study raises many
questions that will be important to
address in the context of understanding
the biology of MeCP2-dependent regula-
tion of cellular function and the etiology
underlying devastating Rett Syndrome
phenotypes. First, how do peripheral
macrophage populations contribute to
somatic impairments observed in Rett
Syndrome? In addition, it will be impor-
tant to understand the significance of
pre-phenotypic changes in peripheral
macrophages, particularly given that
mechanisms underlying the initiation of
phenotypic stagnation and regression in
Rett Syndrome are relatively unknown.ImmunityGiven that changes in peripheral macro-
phage populations occurs early, this
dysregulation of the peripheral immune
system might be an important contrib-
utor to disease onset and/or early pro-
gression. Furthermore, although some
data suggest a direct interaction with
the macrophage genome (Fkbp5), it re-
mains unclear to what extent MeCP2 is
directly affecting macrophages versus
a secondary cellular response to the
abnormal extracellular milieu in MeCP2-
null mice. Experiments in which MeCP2
is ablated in specific macrophage popu-
lations versus global deficiency in
MeCP2 will be necessary to address
this question. Finally, it remains unknown
why some macrophage populations are
more vulnerable than others. Answers
to this question could have important im-
plications for not only understanding
the biology of MeCP2-dependent regula-
tion of gene transcription but also could
be translated to the CNS, where certain
cell populations are particularly vulner-
able to disruptions in MeCP2 (e.g., inhib-
itory neurons) (Chao et al., 2010).
It is clear that peripheral macrophages
are, indeed, regulated by MeCP2 and
might be important contributors to so-
matic disease; however, the contributions
to the neurological deficits remain unclear.
Given that there is increasing evidence
for extensive crosstalk between the cen-
tral nervous system and immune system,
each having profound impact on the
other, even under healthy, steady-state
conditions, one of the major questions
that arises is do MeCP2-dependent
changes in macrophage populations
affect neurological phenotypes? Emerg-
ingwork in thedeveloping brain implicates
microglia, the resident brain immune
cell, and molecules well-established to
function in peripheral immunity (e.g.,
MHC class I, complement, etc.) in brain
development and shaping synaptic con-
nectivity (Boulanger, 2009). For example,
during development, synaptic connec-
tions between neurons form in excess.
These synapses compete for territory
where the more active synaptic connec-
tion ‘‘wins’’ and the less active synapse
‘‘loses’’ and is eliminated from the circuit.
Recent work has demonstrated that mi-
croglia can engulf the less active synaptic
connections and play roles in maturation
of neural circuits (Schafer et al., 2013).
In mouse models of Rett Syndrome42, April 21, 2015 ª2015 Elsevier Inc. 601
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postmortem brain tissue, it is clear that
synaptic circuits are abnormal, often
characterized by a weakening and/or
loss of synapses (Banerjee et al., 2012;
Guy et al., 2011). Could the resident
brain macrophage, microglia, contribute
to this abnormal brain wiring in Rett
Syndrome? This is particularly interesting
given the abnormalities observed in
phagocytic function and inflammatory
pathways inMeCP2-null microglia (Cronk
et al., 2015; Derecki et al., 2012). Under-
standing the contribution of this resident
tissue macrophage to synaptic circuit
development and maintenance in Rett
Syndrome will be important and impactful
(Figure 1).
In summary, the manuscript by Cronk
et al. offers important insights into the
broad range of effects MeCP2 can have
outside the context of the central nervous
system, a largely unexplored aspect of
Rett Syndrome. On a molecular level,
this is the first paper to demonstrate602 Immunity 42, April 21, 2015 ª2015 ElsevMeCP2-dependent regulation of macro-
phage gene expression. On a cellular
level, this paper is the first to demonstrate
that subsets of macrophage populations
are particularly vulnerable to loss of
MeCP2 early in disease progression,
data which might be important for identi-
fying mechanisms of Rett Syndrome
onset and developmental regression.
Taken together, this work is a beautiful
example of how the immune and nervous
systems are intimately associated,
sharing common molecular pathways
and potentially affecting the function of
one another in many dynamic ways. Deci-
phering how immune cells throughout our
body affect a devastating neurological
disorder, Rett Syndrome, will be critical
steps going forward.REFERENCES
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The organism needs to tailor the intestinal inflammatory response to pathogenic bacteria and to pathobionts
that are only occasionally pathogenic. In this issue of Immunity, Seo et al. (2015) show that the pathobiont
Proteus mirabilis induces NLRP3 inflammasome-dependent interleukin-1b (IL-1b) release from CCR2+
Ly6Chigh inflammatory monocytes.In the famous eponymous episode of Star
Trek, the captain of the ship is split into
two different people, one evil and the
other virtuous, implying that both good
and bad perpetually exist in all of us. Is it
the same truth for the gut microbes?
What does it mean to be a pathobiont?
Do we suspect them of ‘‘going off the
rails’’ at random and becoming vicious
pathogens, or is there a hidden logic to
that? It has been long suspected that bac-
terial environmental stimuli, conditioned
by the inflammatory and immunologicalstate of the host, are the primary trigger
of the transformation of a commensal
microbe into a pathogen, and the exam-
ples are numerous. In this issue of Immu-
nity, Seo et al. (2015) have added a new
ingredient into the mix.
They provide data supporting a model
in which the host largely ignores the toxins
of the known pathobiont P. mirabilis until,
in response to the induction of colitis by
dextran sulfate sodium (DSS) treatment,
blood inflammatory monocytes express-
ing the inflammasome NOD-like receptorprotein-3 (NLRP3) arrive at the site of
inflammation (Figure 1). P. mirabilis acti-
vates the inflammasome and directs
the secretion of the interleukin-b (IL-1b)
cytokine that is necessary for induction
of colitis. Several conflicting reports
have been previously published indicating
either a protective or pro-colitogenic role
of NLRP3 and IL-1. The authors now pro-
pose that this discrepancy is explained by
the variable presence of hemolysin hpmA
producing P. mirabilis in the microbial
community of the gut (Seo et al., 2015).
